Juniper Pharmaceuticals (JNP) 10-Q 9 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 03, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Trading Symbol	JNP
Entity Registrant Name	JUNIPER PHARMACEUTICALS INC
Entity Central Index Key	821,995
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		11,319,757

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 20,826	$ 21,446
Accounts receivable, net	10,772	4,734
Inventories	6,280	6,326
Prepaid expenses and other current assets	3,228	3,467
Total current assets	41,106	35,973
Property and equipment, net	17,074	15,229
Intangible assets, net	587	744
Goodwill	8,928	9,123
Other assets	73	151
Total assets	67,768	61,220
Liabilities and stockholders’ equity
Accounts payable	7,173	4,038
Accrued expenses and other	7,398	5,615
Deferred revenue	887	6,141
Current portion of long-term debt	544	546
Total current liabilities	16,002	16,340
Long-term debt, net of current portion	2,909	3,253
Deferred tax liability	300
Other non-current liabilities	64	115
Total liabilities	19,275	19,708
Stockholders’ equity:
Common stock $0.01 par value; 150,000 shares authorized; 12,525 issued and 11,105 outstanding at June 30, 2018 and 12,257 issued and 10,844 outstanding at December 31, 2017	125	123
Additional paid-in capital	294,584	292,108
Treasury stock (at cost), 1,420 shares at June 30, 2018 and 1,413 shares at December 31, 2017	(8,661)	(8,601)
Accumulated deficit	(233,802)	(238,961)
Accumulated other comprehensive loss	(3,753)	(3,157)
Total stockholders’ equity	48,493	41,512
Total liabilities and stockholders’ equity	$ 67,768	$ 61,220

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	12,525,000	12,257,000
Common stock, shares outstanding	11,105,000	10,844,000
Purchase of treasury shares	1,420,000	1,413,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues
Product revenues	$ 9,343,000	$ 9,569,000	$ 19,417,000	$ 17,295,000
Service revenues	5,717,000	4,387,000	11,167,000	7,908,000
License revenues	250,000		250,000
Total revenues	15,310,000	13,956,000	30,834,000	25,203,000
Cost of product revenues	6,158,000	5,303,000	12,174,000	9,617,000
Cost of service revenues	2,959,000	2,347,000	5,969,000	4,590,000
Total cost of revenues	9,117,000	7,650,000	18,143,000	14,207,000
Gross profit	6,193,000	6,306,000	12,691,000	10,996,000
Operating expenses
Sales and marketing	563,000	410,000	982,000	788,000
Research and development	1,055,000	1,648,000	2,029,000	2,994,000
General and administrative	6,518,000	4,604,000	10,607,000	9,025,000
Total operating expenses	8,136,000	6,662,000	13,618,000	12,807,000
Loss from operations	(1,943,000)	(356,000)	(927,000)	(1,811,000)
Interest expense, net	(29,000)	(30,000)	(74,000)	(58,000)
Other income, net	758,000	10,000	559,000	52,000
Total non-operating income (expense)	729,000	(20,000)	485,000	(6,000)
Loss before income taxes	(1,214,000)	(376,000)	(442,000)	(1,817,000)
Income tax expense	300,000	0	300,000	0
Net loss	(1,514,000)	(376,000)	(742,000)	(1,817,000)
Adjustments attributable to preferred stockholders		452,000		445,000
Net (loss) income available to common stockholders	$ (1,514,000)	$ 76,000	$ (742,000)	$ (1,372,000)
Basic net (loss) income per common share	$ (0.14)	$ 0.01	$ (0.07)	$ (0.13)
Diluted net (loss) income per common share	$ (0.14)	$ (0.03)	$ (0.07)	$ (0.13)
Basic weighted average common shares outstanding	11,103	10,803	11,023	10,803
Diluted weighted average common shares outstanding	11,103	10,954	11,023	10,803

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (1,514)	$ (376)	$ (742)	$ (1,817)
Other comprehensive (loss) income components:
Foreign currency translation	(1,536)	823	(596)	1,051
Total other comprehensive (loss) income	(1,536)	823	(596)	1,051
Comprehensive (loss) income	$ (3,050)	$ 447	$ (1,338)	$ (766)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Operating activities:
Net loss			$ (742)	$ (1,817)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization			1,211	1,075
Stock-based compensation expense	$ 503	$ 504	1,069	845
Deferred tax liability			300
Changes in operating assets and liabilities:
Accounts receivable			(6,188)	(145)
Inventories			46	409
Prepaid expenses and other current assets			487	(240)
Accounts payable			2,915	(805)
Accrued expenses and other			1,898	(335)
Deferred rent			(23)	(18)
Deferred revenue			469	1,522
Net cash provided by operating activities			1,442	491
Investing activities:
Purchases of property and equipment			(3,092)	(1,404)
Net cash used in investing activities			(3,092)	(1,404)
Financing activities:
Proceeds from sale of common stock / exercise of options			1,407
Proceeds from loan facility				954
Proceeds from equipment loans				1,501
Principal payments on debt			(274)	(1,143)
Payments to satisfy employee taxes due on vesting of restricted awards			(60)
Dividends paid				(7)
Net cash provided by financing activities			1,073	1,305
Effect of exchange rate changes on cash and cash equivalents			(43)	78
Net (decrease) increase in cash and cash equivalents			(620)	470
Cash and cash equivalents, beginning of period			21,446	20,994	$ 20,994
Cash and cash equivalents, end of period	$ 20,826	21,464	20,826	21,464	21,446
Supplemental cash flow information
Cash paid for interest			75	50
Supplemental noncash information
Purchases of equipment through accounts payable and accrued expenses			$ 470	327
Series C Preferred Stock [Member]
Supplemental noncash information
Excess of carrying value of Series C Preferred Stock over redemption value		$ 459		459	$ 500
Redemption of Series C Preferred Stock and dividend included in accounts payable				$ 98

Interim Condensed Consolidated

Interim Condensed Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Interim Condensed Consolidated Financial Statements	(1) Interim Condensed Consolidated Financial Statements The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the consolidated financial statements and related notes that appear in the Annual Report on Form 10-K of Juniper Pharmaceuticals, Inc. (“Juniper” or the “Company”) for the year ended December 31, 2017 filed with the SEC on March 9, 2018 (the “2017 Annual Report”). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of June 30, 2018, and its results of operations for the three and six months ended June 30, 2018 and 2017, and cash flows for the six months ended June 30, 2018 and 2017. The condensed consolidated balance sheet at December 31, 2017 was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements. Results of operations for the three and six months ended June 30, 2018 are not necessarily indicative of the results for the year ending December 31, 2018 or any period thereafter. At June 30, 2018, cash and cash equivalents were $20.8 million. The Company’s future funding requirements depend on a number of factors, including the rate of market acceptance of its current and future products and services and the resources the Company devotes to developing and supporting the same. The Company believes that current cash and cash equivalents, as well as cash generated from operations, will be sufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months from the date of the filing of this Form 10-Q. The Company may be dependent on its ability to raise additional capital to finance operations. If the Company is not able to raise additional capital on terms acceptable to it, or at all, as and when needed, it may be required to evaluate future anticipated capital or operational needs. Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition, allowance for doubtful accounts, inventory reserves, impairment analysis of goodwill and intangibles including their useful lives, research and development accruals, deferred tax assets, liabilities and valuation allowances, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventories	(2) Inventories Inventories are stated at the lower of cost or market, determined on a first-in, first-out method. The Company monitors standard costs on a monthly basis and updates them annually as necessary to reflect change in raw material costs and labor and overhead rates. Components of inventory cost include materials, labor and manufacturing overhead. Inventories consist of the following (in thousands): June 30, 2018 December 31, 2017 Raw materials $ 1,382 $ 1,921 Work in process 4,060 3,299 Finished goods 838 1,106 Total $ 6,280 $ 6,326 The Company provides inventory allowances when conditions indicate that the selling price could be less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand and reductions in selling prices. The Company balances the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Unfavorable changes in market conditions may result in a need for additional inventory reserves that could adversely impact its gross margins. The inventory reserve balance at June 30, 2018 and December 31, 2017 was $0.2 million and 0.5 million, respectively. No charges for excess and obsolete inventory were incurred during the three months ended June 30, 2018 or 2017. During the six months ended June 30, 2018 and 2017, the Company recorded charges in the condensed consolidated statements of operations for excess and obsolete inventory of $11,000 and $0.2 million, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	(3) Goodwill and Intangible Assets Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. The Company does not amortize its goodwill, but instead tests for impairment annually in the fourth quarter and more frequently whenever events or changes in circumstances indicate that fair value of the asset may be less than the carrying value of the asset. Changes to goodwill during the six months ended June 30, 2018 were as follows (in thousands): Total Balance—December 31, 2017 $ 9,123 Effects of foreign currency translation (195 ) Balance—June 30, 2018 $ 8,928 The Company capitalizes and includes in intangible assets the costs of trademark, developed technology and customer relationships. Intangible assets are recorded at fair value at the time of their acquisition and stated net of accumulated amortization. The Company amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives ranging from 3 to 7 years. The Company evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement and Disclosures, Intangible assets consist of the following at June 30, 2018 and December 31, 2017 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (53 ) (223 ) (201 ) (477 ) Accumulated amortization (247 ) (888 ) (711 ) (1,846 ) Balance—June 30, 2018 $ — $ 259 $ 328 $ 587 Trademark Developed Technology Customer Relationships Total Gross carrying amount $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (53 ) (198 ) (179 ) (430 ) Accumulated amortization (247 ) (839 ) (650 ) (1,736 ) Balance—December 31, 2017 $ — $ 333 $ 411 $ 744 Amortization expense for the three months ended June 30, 2018 and 2017 was $0.1 million. Amortization expense for the six months ended June 30, 2018 and 2017 was $0.2 million and $0.2 million, respectively. Amortization expense related to developed technology is classified as a component of cost of service revenues in the accompanying consolidated statements of operations. Amortization expense related to trademark and customer relationships is classified as a component of general and administrative expenses in the accompanying consolidated statements of operations. As of June 30, 2018, amortization expense remaining on existing intangible assets is as follows (in thousands): Year ending December 31, Total Remainder of 2018 $ 142 2019 256 2020 189 Total $ 587

Debt and Other Contractual Obli

Debt and Other Contractual Obligations	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt and Other Contractual Obligations	(4) Debt and Other Contractual Obligations In September 2013, Juniper assumed debt of $3.9 million in connection with its acquisition of Juniper Pharma Services (“JPS”). JPS had entered into a Business Loan Agreement (“Loan Agreement”) covering three loan facilities (collectively referred to as the “original agreements”) with Lloyds TSB Bank (“Lloyds”) as administrative agent. In May 2017, JPS repaid one of the existing loan facilities upon which JPS subsequently entered into a new loan facility with the same administrative agent for the same outstanding balance. The refinancing was accounted for as a modification with no resulting gain or loss. The remaining original agreements and the new agreement are collectively referred to as the “loan facilities”. As of June 30, 2018, the Company owed $2.3 million on the loan facilities. All facilities are due for repayment over periods ranging from 7-15 years from the date of drawdown. Two of the facilities bear interest at the Bank of England’s base rate plus 1.95%, and 2.55%, respectively. The weighted average interest rates at June 30, 2018 for these two facilities were 2.45% and 3.05%, respectively. The third facility is a fixed rate agreement bearing interest at 2.99% per annum. The weighted average interest rate for the three loan facilities for the three months ended June 30, 2018 was 2.76%. The loan facilities are secured by the mortgaged property and an unlimited lien on other assets of JPS. The loan facilities contain financial covenants that limit the amount of indebtedness Juniper Pharma Services may incur, requires Juniper Pharma Services to maintain certain levels of net worth, and restricts Juniper Pharma Services’ ability to materially alter the character of its business. As of June 30, 2018, the Company is in compliance with all of the covenants under the loan facilities. As of June 30, 2018, the Company owed $1.2 million on its equipment loans. During the quarter ending March 31, 2017, the Company entered into two loans totaling $1.5 million with payments through March 2022 for equipment in its Nottingham, U.K. facility at an interest rate of 2.09%. The transactions were considered failed sales-leaseback arrangements as the Company will obtain title to the equipment at the end of the term of the financing for little or no consideration. These failed sale-leaseback arrangements have been recorded as a component of long-term debt on the Company’s condensed consolidated balance sheets. The initial terms of the loans are 60 months. In October 2015, the Company entered into an operating lease agreement for its corporate office in Boston, Massachusetts. The initial term of the lease agreement is approximately 39 months and ends in the January of 2019, which includes a three-month free rent period. In December 2016, the Company entered into an API Supply Agreement for a manufacturer of progesterone under which the Company has agreed to annual minimum volume commitments until December 2019. The Company’s significant outstanding contractual obligations relate to operating leases for the Company’s facilities, loan agreements and minimum volume commitments. The Company’s facility leases are non-cancellable and contain renewal options. The Company’s future contractual obligations as of June 30, 2018 include the following (in thousands): Total Remainder of 2018 2019 2020 2021 2022 Thereafter Operating lease obligations $ 296 $ 222 $ 74 $ — $ — $ — $ — Loan principal repayments 2,255 116 237 243 250 257 1,152 Capital lease obligations 1,198 154 317 331 344 52 Minimum purchase obligation 5,375 3,401 1,974 — — — — Total $ 9,124 $ 3,893 $ 2,602 $ 574 $ 594 $ 309 $ 1,152

Intravaginal Ring Technology Li

Intravaginal Ring Technology License	6 Months Ended
	Jun. 30, 2018
Licensing Activities [Abstract]
Intravaginal Ring Technology License	(5) Intravaginal Ring Technology License In March 2015, the Company obtained an exclusive worldwide license (“License Agreement”) to the intellectual property rights for a novel segmented intravaginal ring (“IVR”) technology. Due to its novel polymer and segmentation composition, the Company believes the IVR has the potential to deliver one or more drugs, including hormones and larger molecules such as peptides, at different dosages and release rates within a single segmented ring. Drugs such as progesterone and leuprolide have already been tested using the technology and demonstrated sustained release for up to three weeks. This technology was developed by Dr. Robert Langer from the Massachusetts Institute of Technology (“MIT”) and Dr. William Crowley from Massachusetts General Hospital (“MGH”) and Harvard Medical School. Drs. Langer and Crowley each agreed to serve a three-year term, which ended in March 2018, as strategic advisors to the Company in exchange for an upfront one-time payment plus quarterly fees and equity compensation. Unless earlier terminated by the parties, the License Agreement will remain in effect until the later of (i) the date on which all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned and (ii) one year after the last sale for which a royalty is due under the License Agreement or 10 years after such expiration or abandonment date referred to in (i), whichever is earlier. Juniper has the right to terminate the License Agreement by giving 90 days advance written notice to MGH. MGH has the right to terminate the License Agreement based on the Company’s failure to make payments due under the License Agreement, subject to a 15 day cure period, or the Company’s failure to maintain the insurance required by the License Agreement. MGH may also terminate the License Agreement based on Juniper’s non-financial default under the License Agreement, subject to a 60 day cure period. Pursuant to the terms of the License Agreement, Juniper has agreed to reimburse MGH for all costs associated with the preparation, filing, prosecution and maintenance of the licensed patent rights, and has agreed to pay MGH a $50,000 annual license fee on each of the first five year anniversaries of the effective date of the License Agreement, and a $100,000 annual license fee beginning on the sixth anniversary of the effective date of the License Agreement and on each subsequent anniversary thereafter. The annual license fee is creditable against any royalties or sublicense income payable in each calendar year. Under the terms of the License Agreement, Juniper has agreed to use commercially reasonable efforts to develop and commercialize at least one product and/or process related to the IVR technology, which efforts will include the making of certain minimum annual expenditures in each of the first five years following the effective date of the License Agreement. Juniper has also agreed to pay MGH certain milestone payments totaling up to $1.2 million tied to the Company’s achievement of certain development and commercialization milestones, and certain annual royalty payments based on net sales of any such patented products or processes developed by Juniper. Daré Bioscience, Inc. On April 24, 2018, Juniper entered into an Exclusive License Agreement with Daré Bioscience, Inc. (Daré), the “Daré License Agreement”) pursuant to which the Company granted Daré (a) an exclusive worldwide license under certain patent rights (i) owned by the Company and (ii) exclusively licensed to the Company under the License Agreement, dated as of March 25, 2015, by and between Juniper and The General Hospital Corporation, as amended, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive worldwide license under certain technological information owned by the Company to make, have made, use, have used, sell, have sold, import and have imported products and processes. Daré is also entitled to sublicense the rights granted to it under the Daré License Agreement. As consideration, the Company received in May 2018 a $250,000 license fee from Daré in connection with the execution of the Daré License Agreement. In addition, the Company is entitled to receive an annual license maintenance fee from Daré in the amount of $50,000 for the first two anniversaries of the effective date of the Daré License Agreement, increasing to $100,000 for each anniversary thereafter. The Company is also entitled to receive potential future development and sales milestone payments of up to $43.8 million (up to $13.5 million in development milestones and up to $30.3 million in sales milestones) for each product or process covered by the licenses granted under the Daré License Agreement. The Company is also eligible to receive mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the Daré Licensee Agreement. The royalty term shall terminate on a product-by-product basis (or process-by-process) basis on the latest of (i) the expiration date of the last valid claim within the licensed patent rights in a country, (ii) ten (10) years following the first commercial sale of a product or process in a country, or (iii) the entry of generic competition for a product or process in a country, provided that if there is no generic competition for a product or process in a country by the ten (10) year anniversary of the first commercial sale of a product or process in a country, the royalty term shall terminate on the ten (10) year anniversary of the first commercial sale of such product or process in the country. In addition, if Daré sublicenses any of its rights under the Daré License Agreement, the Company is eligible to a low double-digit percentage of all sublicense income received by Daré for the sublicense of such rights to a third party, in lieu of the royalties on net sales noted above.

Segments and Geographic Informa

Segments and Geographic Information	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Segments and Geographic Information	(6) Segments and Geographic Information The Company and its subsidiaries currently operate in two segments, product and service. The product segment oversees the supply chain and manufacturing of Crinone, the Company’s sole commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services for the Company’s customers as well as characterizing and developing pharmaceutical product candidates for the Company’s internal programs. The Company conducts its advanced formulation, analytical and consulting services through its subsidiary, Juniper Pharma Services, the Company’s U.K.-based provider of pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services to the pharmaceuticals industry. The Company has integrated its supply chain management for Crinone into those operations and has therefore sought to capture synergies by transferring all operational activities related to its historic business. The Company owns certain plant and equipment physically located at third-party contractor facilities in the United Kingdom (the “U.K.”) and Switzerland. The Company’s largest customer, Merck KGaA, utilizes a Switzerland-based subsidiary to acquire product from the Company, which it then sells throughout the world, excluding the United States (the “U.S.”). The following tables show selected information by geographic area (in thousands): Revenues: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 United States $ 3,917 $ 2,387 $ 7,459 $ 4,015 Switzerland 9,518 9,759 19,796 17,516 United Kingdom 1,182 1,088 1,975 2,037 Other countries 693 722 1,604 1,635 Total $ 15,310 $ 13,956 $ 30,834 $ 25,203 Total assets: June 30, 2018 December 31, 2017 United States $ 20,886 $ 21,683 Switzerland 7,362 1,366 United Kingdom 39,491 38,129 Other countries 29 42 Total $ 67,768 $ 61,220 Long-lived assets: June 30, 2018 December 31, 2017 United States $ 345 $ 523 Switzerland 1,257 535 United Kingdom 16,129 15,064 Other countries 3 2 Total $ 17,734 $ 16,124 Long-lived assets include fixed assets, intangibles and other assets. No other individual country represented greater than 10% of total revenues, total assets or total long-lived assets for any period presented. For the three and six months ended June 30, 2018 and 2017, Merck KGaA accounted for 100% of the product segment revenue. At June 30, 2018 and December 31, 2017, Merck KGaA made up 100% of the product segment accounts receivable. For the three and six months ended June 30, 2018 and 2017, the same customer accounted for 41% and 28% and 37% and 23% of the service segment total revenue, respectively. No additional customers accounted for 10% or more of the service segment total revenue for the three or six months ended June 30, 2018 and 2017. At June 30, 2018 and December 31, 2017, one customer accounted for 47% and 53% of total service segment accounts receivable, respectively. The following summarizes other information by segment for the three months ended June 30, 2018 (in thousands): Product Service Total Revenues Product revenues $ 9,343 $ — $ 9,343 Service revenues — 5,717 5,717 License revenues 250 — 250 Total revenues $ 9,593 $ 5,717 $ 15,310 Cost of product revenues 6,158 — 6,158 Cost of service revenues — 2,959 2,959 Total cost of revenues $ 6,158 $ 2,959 $ 9,117 Gross profit $ 3,435 $ 2,758 $ 6,193 Total operating expenses 8,136 Total non-operating income 729 Loss before income taxes $ (1,214 ) The following summarizes other information by segment for the three months ended June 30, 2017 (in thousands): Product Service Total Revenues Product revenues $ 9,569 $ — $ 9,569 Service revenues — 4,387 4,387 Total revenues $ 9,569 $ 4,387 $ 13,956 Cost of product revenues 5,303 — 5,303 Cost of service revenues — 2,347 2,347 Total cost of revenues $ 5,303 $ 2,347 $ 7,650 Gross profit $ 4,266 $ 2,040 $ 6,306 Total operating expenses 6,662 Total non-operating expense (20 ) Loss before income taxes $ (376 ) The following summarizes other information by segment for the six months ended June 30, 2018 (in thousands): Product Service Total Revenues Product revenues $ 19,417 $ — $ 19,417 Service revenues — 11,167 11,167 License revenues 250 — 250 Total revenues $ 19,667 $ 11,167 $ 30,834 Cost of product revenues 12,174 — $ 12,174 Cost of service revenues — 5,969 $ 5,969 Total cost of revenues $ 12,174 $ 5,969 18,143 Gross profit $ 7,493 $ 5,198 $ 12,691 Total operating expenses 13,618 Total non-operating income 485 Loss before income taxes $ (442 ) The following summarizes other information by segment for the six months ended June 30, 2017 (in thousands): Product Service Total Revenues Product revenues $ 17,295 $ — $ 17,295 Service revenues — 7,908 7,908 Total revenues $ 17,295 $ 7,908 $ 25,203 Cost of product revenues $ 9,617 $ — $ 9,617 Cost of service revenues — 4,590 4,590 Total cost of revenues $ 9,617 $ 4,590 $ 14,207 Gross profit $ 7,678 $ 3,318 $ 10,996 Total operating expenses 12,807 Total non-operating expense (6 ) Loss before income taxes $ (1,817 )

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Property and Equipment	(7) Property and Equipment Property and equipment consists of the following (in thousands): Estimated Useful Life (Years) June 30, 2018 December 31, 2017 Machinery and equipment 3-10 $ 15,061 $ 12,358 Furniture and fixtures 3-5 1,083 1,083 Computer equipment and software 3-5 635 628 Buildings Up to 39 7,824 7,995 Land Indefinite 502 513 Construction in-process 1,387 1,133 26,492 23,710 Less: Accumulated depreciation (9,418 ) (8,481 ) Total $ 17,074 $ 15,229 Depreciation expense for the three and six months ended June 30, 2018 and 2017 was $0.5 million and $0.5 million and $1.1 million and $0.9 million, respectively. Machinery and equipment includes $1.5 million of equipment purchased under equipment loans at June 30, 2018 and December 31, 2017.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Shareholders' Equity	(8) Shareholders’ Equity Preferred Stock During the quarter ending June 30, 2017, the Company issued a Notice of Conversion to the holders of its Series B and a Notice of Redemption to the holders of its Series C giving notice that on June 30, 2017 (the “Redemption and Conversion Date”) all outstanding shares of the respective Preferred Stock issuance would be converted, as in the case of the Series B, or redeemed, as in the case of the Series C. The Series B, by its terms, automatically converted into shares of common stock, upon the occurrence of the event. On the Redemption and Conversion Date, each share of the 130 shares of Series B outstanding converted into 2.78 shares of common stock resulting in an issuance of 361 shares. The holders of each share of the 550 shares of Series C outstanding had the right to require the Company to redeem their shares in cash plus all accrued and unpaid dividends thereon the date such redemption is demanded. On the Redemption and Conversion Date, the Company paid to the holders of the Series C approximately $0.01 million and as a result of the transaction recorded the excess of the carrying value of Series C over redemption value of approximately $0.5 million to accumulated deficit for the year ended December 31, 2017. There are no outstanding shares of either the Series B or the Series C at June 30, 2018 or December 31, 2017.

Net (Loss) Income Per Common Sh

Net (Loss) Income Per Common Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Net (Loss) Income Per Common Share	(9 ) Net (Loss) Income Per Common Share The calculation of basic and diluted income (loss) per common share and common share equivalents is as follows (in thousands except for per share data): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Basic net (loss) income per common share Net loss $ (1,514 ) $ (376 ) $ (742 ) $ (1,817 ) Add: Excess of carrying value of Series C Preferred Stock over redemption value — 459 459 Less: Preferred stock dividends — (7 ) — (14 ) Net (loss)income applicable to common stock $ (1,514 ) $ 76 $ (742 ) $ (1,372 ) Basic weighted average number of common shares outstanding 11,103 10,803 11,023 10,803 Basic net (loss) income per common share $ (0.14 ) $ 0.01 $ (0.07 ) $ (0.13 ) Diluted income (loss) per common share Net (loss) income applicable to common stock $ (1,514 ) $ 76 $ (742 ) $ (1,372 ) Less: Excess of carrying value of Series C Preferred Stock over redemption value — (459 ) — — Add: Preferred stock dividends — 7 — — Net loss applicable to dilutive common stock $ (1,514 ) $ (376 ) $ (742 ) $ (1,372 ) Basic weighted average number of common shares outstanding 11,103 10,803 11,023 10,803 Effect of dilutive securities Dilutive stock awards — 40 — — Dilutive preferred share conversion 111 — 151 — — Diluted weighted average number of common shares outstanding 11,103 10,954 11,023 10,803 Diluted net (loss) income per common share $ (0.14 ) $ (0.03 ) $ (0.07 ) $ (0.13 ) Basic net (loss) income per common share is computed by dividing the net (loss) income, less preferred dividends and adding the excess of carrying value of Series C Preferred Stock over redemption value recognized on the conversion of the Series C Preferred Shares by the weighted-average number of shares of common stock outstanding during a period. The diluted income (loss) per common share calculation gives effect to dilutive options, convertible preferred stock, and other potential dilutive common stock including restricted shares of common stock outstanding during the period. Diluted net (loss) income per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options, assuming the exercise of all in-the-money stock options. Common share equivalents have been excluded where their inclusion would be anti-dilutive. Shares to be issued upon the exercise of the outstanding options, performance-based restricted stock units, convertible preferred stock, and selected restricted shares of common stock excluded from the income per share calculation amounted to 2.0 million and 2.4 million and 2.0 million and 1.5 million in each of the three and six months ended June 30, 2018 and 2017, respectively, because the awards were anti-dilutive.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Accumulated Other Comprehensive Loss	(10) Accumulated Other Comprehensive Loss Changes to accumulated other comprehensive loss during the six months ended June 30, 2018 were as follows (in thousands): Translation Adjustment Balance—December 31, 2017 $ (3,157 ) Current period other comprehensive income (596 ) Balance—June 30, 2018 $ (3,753 )

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	(11) Stock-Based Compensation Stock Incentive Plan – Stock Options Juniper granted options to purchase 293,500 and 680,400 shares of common stock to employees during the six months ended June 30, 2018 and 2017, respectively. There were no options granted to non-employees during the six months ended June 30, 2018 and 2017. Stock options granted to employees typically vest over a four-year term and options granted to non-employee directors typically vest over a three-year term. The Company uses the Black-Scholes option pricing model to determine the estimated grant date fair values for stock-based awards. The Black-Scholes o ption pricing model requires the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The weighted-average grant date fair values of options granted to employees during the six months ended June 30, 2018 and 2017 were $3.40 and $2.43, respectively, using the following assumptions: Six Months Ended June 30, 2018 2017 Risk free interest rate 2.15% 1.45% - 1.59% Expected term 4.75 years 4.5 - 4.75 years Dividend yield — — Expected volatility 47.79% - 47.86% 53.15% - 55.20% The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options, which is re-measured over the graded vesting term resulting in periodic adjustments to stock-based compensation expense. The stock-based compensation expense recorded for non-employees has historically been reflected in the research and development line of the statement of operations and is remeasured on a quarterly basis from the date of grant. The Company did not record any stock-based expense for non-employee awards during the three or six months ended June 30, 2018 as all options were fully vested. During the three and six months ended June 30, 2017, the Company recorded a reduction of stock-based compensation expense of $0.1 million for non-employee options as a result of changes in the fair value of the options during the period. Stock Option Plan – Restricted Stock Juniper granted 122,300 and 5,625 time-based restricted stock units to employees and non-employee directors, respectively, during the six months ended June 30, 2018. The Company granted 52,700 time-based restricted stock units to employees and 51,234 to non-employee directors during the six months ended June 30, 2017. The weighted-average grant date fair value of the time-based restricted stock units was $8.18 and $5.11 per share during the six months ended June 30, 2018 and 2017, respectively. The Company recognizes stock-based compensation expense for time-based restricted stock units over the vesting period. There were 9,300 time-based restricted stock units that vested during the six months ended June 30, 2018. No time-based restricted stock units vested during the six months ended June 30, 2017. The Company granted 186,000 performance-based restricted stock units to employees during the six months ended June 30, 2017. No additional performance-based restricted stock units were granted during the six months ended June 30, 2018. These performance-based restricted stock units vest based upon the occurrence of certain operational and strategic events that were determined by the Company’s Board of Directors and approved by the Company’s Compensation Committee. The Company considers the performance criteria at each balance sheet date and recognizes stock-based compensation expense for those criteria considered probable. During the year ended and at December 31, 2017, 109,550 performance-based restricted stock units expired. At December 31, 2017, performance-based restricted stock units outstanding totaled 76,450. On January 8, 2018, the Company announced the 4.5-year extension of its supply agreement for Crinone with an affiliate of Merck KGaA, Darmstandt, Germany. On February 7, 2018, the Company’s Compensation Committee of the Board of Director approved the vesting of 27,800 awards affiliated with this performance condition and as a result the Company recorded a charge to stock compensation expense during the first quarter of 2018 totaling $0.1 million. At June 30, 2018, performance-based restricted stock units outstanding totaled 48,650. The expense recognition for these awards commences when achievement of the operational or strategic events becomes probable over the remaining service period. In the second quarter, the Company determined the achievement of one remaining performance criteria associated with a targeted organic revenue growth of Juniper Pharma Services, totaling 20,850 restricted stock units, was probable and as a result recognized $36,000 in stock-based compensation expense during the three months ended June 30, 2018. Stock-based compensation relates to options granted to employees, non-employee directors and non-employees, time-based restricted stock units granted to employees and non-employee directors and performance-based restricted stock units granted to employees. Stock-based compensation expense for the three months ended June 30, 2018 and 2017 was $0.5 million and $0.5 million, respectively. Stock-based compensation expense for the six months ended June 30, 2018 and 2017 was $1.1 million and $0.8 million, respectively. Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective awards as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Cost of revenues $ 39 $ 31 $ 77 $ 59 Sales and marketing 12 12 25 23 Research and development 40 71 58 28 General and administrative 412 390 909 735 Total $ 503 $ 504 $ 1,069 $ 845 There were 230,626 of stock option exercised during the six months ended June 30, 2018 for which the Company received $1.4 million. There were no option exercises during the six months ended June 30, 2017. As of June 30, 2018, the total unrecognized compensation cost related to outstanding stock options and time-based restricted stock units expected to vest was $3.6 million, which the Company expects to recognize over a weighted-average period of 2.58 years.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(12) Fair Value of Financial Instruments The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported values. ASC 820 establishes a framework for measuring fair value U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: Level 1: Quoted prices in active markets for identical assets and liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of cash and cash equivalents are classified as Level 1 at June 30, 2018 and December 31, 2017. Some of the estimates and assumptions in the Company's goodwill impairment assessment include: the amount and timing of the projected net cash flows, the discount rate, and the tax rate. The fair values of accounts receivable and accounts payable approximate their respective carrying amounts. The Company’s long-term debt is carried at amortized face value, which approximates fair value based on current market pricing of similar debt instruments and is categorized as a Level 2 measurement. The Company did not have transfers of financial assets between Level 1 and Level 2.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes Provision for income taxes for the three and six months ended June 30, 2018 was $0.3 million. Income tax expense primarily relates to increased current year profits in the U.K. and adjustments resulting from the filing of the U.K. tax returns, offset by a benefit for releasing the valuation allowance on net deferred tax assets in the U.K.. During the three and six months ended June 30, 2017, Juniper recorded no income tax expense due to expected losses forecasted for the year due to the full valuation allowance in all jurisdictions. As of each reporting date, the Company’s management considers new evidence, both positive and negative, that could impact management’s view with regard to future realization of deferred tax assets. The Company continues to maintain valuation allowances in the U.S. and France. On December 22, 2017 President Donald Trump signed into U.S. law the Tax Cuts and Jobs Act of 2017 (“Tax Reform”). ASC Topic 740, Accounting for Income Taxes One of the Tax Reform provisions effective January 1, 2018 includes a minimum tax on certain foreign earnings in excess of 10% of the foreign subsidiaries tangible assets (i.e., global intangible low-taxed income or “GILTI”). Under the U.S. generally accepted accounting principles, companies are allowed to make an accounting policy election of either (i) account for GILTI as a component of tax expense in the period in which the Company is subject to the rules (the “period cost method”), or (ii) account for GILTI in the Company’s measurement of deferred taxes (the “deferred method”). The Company is currently accounting for GILTI using the period cost method as it continues to evaluate the two policies available. Under the period cost method, the Company has included approximately $2.4 million GILTI in U.S. taxable income, fully off-set by net operating loss carryforwards. Given the significance of the legislation, the FASB issued ASU No. 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 Tax Reform included a mandatory one-time tax on accumulated earnings of foreign subsidiaries, and as a result, all previously unremitted earnings for which no U.S. deferred tax liability had been accrued have now been subject to U.S. tax. Notwithstanding the U.S. taxation of these amounts, the Company intends to continue to invest all of these earnings, as well as the capital in these subsidiaries, indefinitely outside of the U.S. The amount of any unrecognized deferred tax liability on these undistributed earnings would be immaterial. The Company files tax returns in the United States, United Kingdom, France and various state jurisdictions. All of the Company’s tax years remain open to examination by major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in past years may still be adjusted upon examination by the Internal Revenue Service or state and foreign tax authorities if they have or will be used in future periods. The Internal Revenue Service has concluded their audit of the 2011 and 2012 tax years. There were no material findings resulting from their audit. Additionally, with few exceptions, Juniper is no longer subject to U.S. state tax examinations for years prior to 2012.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2018
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	(14) Recent Accounting Pronouncements Adopted In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Recognition and Measurement of Financial Assets and Financial Liabilities In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition-Construction-Type and Production-Type Contracts Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net) , Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers To be adopted In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In February 2016, the FASB issued ASU No. 2016-02, Leases

Restructuring Charges

Restructuring Charges	6 Months Ended
	Jun. 30, 2018
Restructuring And Related Activities [Abstract]
Restructuring Charges	(15) Restructuring Charges In September 2017, the Company announced a corporate reprioritization which aimed to re-focus its resources on the core businesses of Crinone progesterone gel and JPS and reduce expenditures on research and development activities associated with the Company’s IVR program with the goal of potentially identifying a partner for one or more of its IVR product candidates. As a result, during the fiscal year ended December 31, 2017, the Company incurred approximately $0.8 million in restructuring charges. The Company accounted for these actions in accordance with ASC 420, Exit or Disposal Cost Obligations The following table summarizes the components of the Company’s restructuring activity recorded in the accompanying balance sheets (in thousands): Amounts accrued at December 31, 2017 Expense incurred Amounts paid Amounts accrued at June 30, 2018 Employee severance, benefits and related costs $ 72 $ — $ (72 ) $ — Obligations under manufacturing and development contracts 283 — (134 ) 149 $ 355 $ — $ (206 ) $ 149 No significant additional charges are anticipated relating to this restructuring plan. The Company expects to pay approximately $43,000 and $0.1 million during the remainder of 2018 and beyond, respectively.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Jun. 30, 2018
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	(16) Revenue from Contracts with Customers The new accounting standard for recognition of revenue, Topic 606, was adopted by the Company for its fiscal year beginning on January 1, 2018. In accordance with Topic 606, the Company recognizes revenue following the five-step model based on the principle that an entity should recognize revenue to depict the transfer of promised goods or services to customers at an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services. The five-step model prescribed under Topic 606 include: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation. The Company adopted Topic 606 using the modified retrospective transition method. In adopting Topic 606, the Company applied the new guidance only to contracts that were not completed on January 1, 2018. The Company does not disclose information about remaining performance obligations that are part of contracts with an original expected duration of one year or less and does not adjust for the effect of the financing components when the period between customer payment and revenue recognition is one year or less, which are practical expedients provided within Topic 606. Product Revenue The adoption of Topic 606 resulted in a change in the pattern of revenue recognition for product revenue. Revenue and the related cost of sales are primarily the result of firm purchase commitments, generally only for a short period of time. Revenue is recognized when the performance obligation has been met, upon shipment to the customer. Selling prices to Merck KGaA for Crinone are determined on an annual and country-by-country basis. Juniper records revenue at a transaction price that most closely approximate what it will be sold for by Merck KGaA. The transaction price is determined by evaluating the Merck KGaA selling price. The Company records as deferred revenue amounts invoiced above the transaction price. Accordingly, product revenue in each period includes both an amount for product shipped to Merck KGaA in the current period recognized at the transaction price and an amount for product shipped by Merck KGaA to its customers in the current period equal to the difference between the invoice price and the transaction price. Product revenue is recorded net of variable consideration which include volume discounts and price adjustments. Merck KGaA is entitled to a volume discount based on annual purchases. The Company records reserves against revenue on a quarterly basis to reflect the volume discount expected to be earned by Merck KGaA during the year. In addition, any difference between selling price to Merck KGaA and Merck KGaA’s actual net selling price are billed or credited to Merck KGaA in the quarter the product is sold through by Merck KGaA. Product sales are recorded net of value-added tax and similar taxes. Shipping and handling costs are recorded in cost of revenue. Upon adoption, the Company recorded approximately $5.7 million as an adjustment to both deferred revenue and accumulated deficit. In accordance with Topic 605, the Company would have recognized approximately $10.3 million and $19.0 million in product revenue for the three and six months ended June 30, 2018 and product deferred revenue as of that date would have been $6.4 million. Service Revenue The adoption of Topic 606 did not have an impact on how the Company recognizes service revenue. Juniper recognizes substantially all of the Company’s professional services revenues under written contracts as the services are provided, and only in those situations where collection from the client is reasonably assured. Contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. When entering into multiple element arrangements, the Company identifies whether its performance obligations under the arrangement represent a distinct good or service or a series of distinct goods or services. A series of distinct goods or services is required to be accounted for as a single performance obligation provided that (i) each distinct good or service in the series promised would meet the criteria to be a performance obligation satisfied over-time; and (ii) the same method would be used to measure the Company’s progress toward complete satisfaction of the performance obligation to transfer each distinct good or service in the series to the customer. If a contract is separated into more than one performance obligation, the Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The fair value of deliverables under the arrangement may be derived using a “best estimate of selling price” if vendor-specific objective evidence and third-party evidence is not available. Significant management judgment is required in determining the consideration to be earned under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. Service revenues from a majority of Juniper’s fixed-price engagements are recognized on a proportional performance method based on the ratio of costs incurred, substantially all of which are labor-related, to the total estimated project costs. The proportional performance method is used for fixed-price contracts because reasonably dependable estimates of the revenues and costs applicable to various stages of a contract can be made, based on historical experience and the terms set forth in the contract, and are indicative of the level of benefit provided to Juniper’s clients. Project costs are classified in costs of services and are based on the direct salary of the employees on the engagement plus all direct expenses incurred to complete the engagement, including any amounts billed to Juniper by its vendors. In the event of a termination, fixed-price contracts generally provide for payment for services rendered up to the termination date. Service revenues also include reimbursements, which include reimbursement for travel and other out-of-pocket expenses, outside consultants, and other reimbursable expenses. Amounts invoiced not yet earned on service revenue are deferred until such time as performance is rendered or the obligation to perform the service is completed for service revenues. The professional service contracts that Juniper enters into and operates under specify whether the engagement will be billed on a time-and-materials or a fixed-price basis. These engagements generally last three to six months, although some of Juniper’s engagements can be longer in duration. Payments terms vary by the type and services offered. The term between invoicing and when payment is due is not significant. In certain cases, Juniper bills clients prior to work being performed, which requires Juniper to defer revenue in accordance with U.S. GAAP. Revenues from time-and-materials service contracts are recognized as the services are performed based upon hours worked and contractually agreed-upon hourly rates, as well as indirect fees based upon hours worked. Juniper collects value-added tax from its customers for revenue generated out of the U.K. for which the customer is not tax exempt and remits such taxes to the appropriate governmental authority. Juniper presents its value added tax on a net basis; therefore, these taxes are excluded form revenues. The Company generally expenses commission when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses. Juniper does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognized revenue at the amount to which it has the right to invoice for services performed. Upon adoption, for contracts that exceed one year in duration, the Company has recorded contract costs totaling $0.2 million. For the three and six months ended June 30, 2018, in accordance with Topic 605, the Company would have recognized a reduction in sales and marketing expense of approximately $39 thousand and $11 thousand, respectively. As of June 30, 2018, the ending balance of contract costs included in prepaid expenses and other current assets was $0.2 million. License Revenue The Company evaluated the Daré License Agreement under ASC 606. Based on this evaluation, the Company identified a single performance obligation requiring the transfer of the intellectual property under the license under which Daré is responsible for conducting all research, development and commercial activities for the IVR program using its available resources. Because the Company satisfied the single performance obligation at the inception of the contract and had no remaining performance obligation, the upfront consideration received of $0.3 million was recognized upon receipt. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales occur. A summary of changes in deferred revenue balances for product and service revenue is as follows: Product Revenue Service Revenue Total Opening Balance - December 31, 2017 $ 5,888 $ 253 $ 6,141 Additions 300 917 1,217 Recognized into Revenue (230 ) (538 ) (768 ) Recognized into Accumulated Deficit (5,703 ) — (5,703 ) Ending Balance - June 30, 2018 $ 255 $ 632 $ 887

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Event	(17) Subsequent Event On July 2, 2018, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Catalent Pharma Solutions, Inc., a Delaware corporation (“Catalent”) and Catalent Boston, Inc., a Delaware corporation and wholly owned subsidiary of Catalent (“Merger Sub”) providing for the acquisition of the Company by Catalent in an all cash transaction, pursuant to a tender offer, followed by a subsequent merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Catalent. Pursuant to the Merger Agreement, and subject to its terms and conditions, on July 17, 2018, Merger Sub commenced a cash tender offer (the “Offer”) to acquire all of our issued and outstanding shares of common stock at a price per share equal to $11.50, net to the seller in cash, without interest, subject to any withholding of taxes required by applicable law and, further, the Offer will initially remain open until the end of the day on August 13, 2018, which is the 20 th The obligation of Merger Sub to consummate the Offer is subject to customary conditions, including, among others, that a certain minimum number of shares of common stock be validly tendered and not validly withdrawn (“Minimum Condition”). Specifically, the Minimum Condition requires that there be validly tendered and not validly withdrawn shares of common stock that, when considered together with all other shares of common stock (if any) beneficially owned by Catalent and its affiliates (excluding any shares of common stock tendered pursuant to guaranteed delivery procedures that have not yet been received), represent more than 50% of the sum of (x) the total number of shares of the Company’s common stock outstanding at the time of the expiration of the Offer, plus (y) the aggregate number of shares of common stock then issuable to optionholders from which the Company has received notices of exercise prior to the expiration of the Offer (and as to which such shares have not yet been issued to such exercising optionholders) . If, at the scheduled expiration time of the Offer any of the conditions to the Offer have not been satisfied or waived, then the Offer may be extended on one or more occasions to permit the satisfaction of all Offer conditions. At the proposed effective time of the Merger, each share of the Company’s common stock issued and outstanding immediately prior to the proposed effective time of the Merger, will be canceled and converted into the right to receive $11.50 in cash, without interest and subject to any required tax withholding, other than: (i) the Company’s shares of common stock held in treasury, (ii) shares of common stock held by Catalent, Merger Sub or any other direct or indirect wholly owned subsidiary of Catalent or Merger Sub, (iii) shares of Common Stock irrevocably accepted for payment in the Offer, (iv) shares of common stock held by stockholders who have properly exercised their demands for appraisal of such shares in accordance with the Delaware law and have neither withdrawn nor lost such rights prior to the effective time of the Merger .

Interim Condensed Consolidate24

Interim Condensed Consolidated Financial Statements (Policies)	6 Months Ended
	Jun. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Management Estimates	Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition, allowance for doubtful accounts, inventory reserves, impairment analysis of goodwill and intangibles including their useful lives, research and development accruals, deferred tax assets, liabilities and valuation allowances, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.
Goodwill and Intangible Assets	Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. The Company does not amortize its goodwill, but instead tests for impairment annually in the fourth quarter and more frequently whenever events or changes in circumstances indicate that fair value of the asset may be less than the carrying value of the asset. The Company capitalizes and includes in intangible assets the costs of trademark, developed technology and customer relationships. Intangible assets are recorded at fair value at the time of their acquisition and stated net of accumulated amortization. The Company amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives ranging from 3 to 7 years. The Company evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement and Disclosures,
Recent Accounting Pronouncements	Adopted In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Recognition and Measurement of Financial Assets and Financial Liabilities In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition-Construction-Type and Production-Type Contracts Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net) , Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers To be adopted In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In February 2016, the FASB issued ASU No. 2016-02, Leases

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following (in thousands): June 30, 2018 December 31, 2017 Raw materials $ 1,382 $ 1,921 Work in process 4,060 3,299 Finished goods 838 1,106 Total $ 6,280 $ 6,326

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Changes to Goodwill	Changes to goodwill during the six months ended June 30, 2018 were as follows (in thousands): Total Balance—December 31, 2017 $ 9,123 Effects of foreign currency translation (195 ) Balance—June 30, 2018 $ 8,928
Changes to Intangible Assets	Intangible assets consist of the following at June 30, 2018 and December 31, 2017 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (53 ) (223 ) (201 ) (477 ) Accumulated amortization (247 ) (888 ) (711 ) (1,846 ) Balance—June 30, 2018 $ — $ 259 $ 328 $ 587 Trademark Developed Technology Customer Relationships Total Gross carrying amount $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (53 ) (198 ) (179 ) (430 ) Accumulated amortization (247 ) (839 ) (650 ) (1,736 ) Balance—December 31, 2017 $ — $ 333 $ 411 $ 744
Amortization Expense Remaining on Existing Intangible Assets	As of June 30, 2018, amortization expense remaining on existing intangible assets is as follows (in thousands): Year ending December 31, Total Remainder of 2018 $ 142 2019 256 2020 189 Total $ 587

Debt and Other Contractual Ob27

Debt and Other Contractual Obligations (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Summary of Future Contractual Obligations	The Company’s future contractual obligations as of June 30, 2018 include the following (in thousands): Total Remainder of 2018 2019 2020 2021 2022 Thereafter Operating lease obligations $ 296 $ 222 $ 74 $ — $ — $ — $ — Loan principal repayments 2,255 116 237 243 250 257 1,152 Capital lease obligations 1,198 154 317 331 344 52 Minimum purchase obligation 5,375 3,401 1,974 — — — — Total $ 9,124 $ 3,893 $ 2,602 $ 574 $ 594 $ 309 $ 1,152

Segments and Geographic Infor28

Segments and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Selected Information by Geographic Area	The following tables show selected information by geographic area (in thousands): Revenues: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 United States $ 3,917 $ 2,387 $ 7,459 $ 4,015 Switzerland 9,518 9,759 19,796 17,516 United Kingdom 1,182 1,088 1,975 2,037 Other countries 693 722 1,604 1,635 Total $ 15,310 $ 13,956 $ 30,834 $ 25,203 Total assets: June 30, 2018 December 31, 2017 United States $ 20,886 $ 21,683 Switzerland 7,362 1,366 United Kingdom 39,491 38,129 Other countries 29 42 Total $ 67,768 $ 61,220 Long-lived assets: June 30, 2018 December 31, 2017 United States $ 345 $ 523 Switzerland 1,257 535 United Kingdom 16,129 15,064 Other countries 3 2 Total $ 17,734 $ 16,124
Schedule of Other Information by Segment	The following summarizes other information by segment for the three months ended June 30, 2018 (in thousands): Product Service Total Revenues Product revenues $ 9,343 $ — $ 9,343 Service revenues — 5,717 5,717 License revenues 250 — 250 Total revenues $ 9,593 $ 5,717 $ 15,310 Cost of product revenues 6,158 — 6,158 Cost of service revenues — 2,959 2,959 Total cost of revenues $ 6,158 $ 2,959 $ 9,117 Gross profit $ 3,435 $ 2,758 $ 6,193 Total operating expenses 8,136 Total non-operating income 729 Loss before income taxes $ (1,214 ) The following summarizes other information by segment for the three months ended June 30, 2017 (in thousands): Product Service Total Revenues Product revenues $ 9,569 $ — $ 9,569 Service revenues — 4,387 4,387 Total revenues $ 9,569 $ 4,387 $ 13,956 Cost of product revenues 5,303 — 5,303 Cost of service revenues — 2,347 2,347 Total cost of revenues $ 5,303 $ 2,347 $ 7,650 Gross profit $ 4,266 $ 2,040 $ 6,306 Total operating expenses 6,662 Total non-operating expense (20 ) Loss before income taxes $ (376 ) The following summarizes other information by segment for the six months ended June 30, 2018 (in thousands): Product Service Total Revenues Product revenues $ 19,417 $ — $ 19,417 Service revenues — 11,167 11,167 License revenues 250 — 250 Total revenues $ 19,667 $ 11,167 $ 30,834 Cost of product revenues 12,174 — $ 12,174 Cost of service revenues — 5,969 $ 5,969 Total cost of revenues $ 12,174 $ 5,969 18,143 Gross profit $ 7,493 $ 5,198 $ 12,691 Total operating expenses 13,618 Total non-operating income 485 Loss before income taxes $ (442 ) The following summarizes other information by segment for the six months ended June 30, 2017 (in thousands): Product Service Total Revenues Product revenues $ 17,295 $ — $ 17,295 Service revenues — 7,908 7,908 Total revenues $ 17,295 $ 7,908 $ 25,203 Cost of product revenues $ 9,617 $ — $ 9,617 Cost of service revenues — 4,590 4,590 Total cost of revenues $ 9,617 $ 4,590 $ 14,207 Gross profit $ 7,678 $ 3,318 $ 10,996 Total operating expenses 12,807 Total non-operating expense (6 ) Loss before income taxes $ (1,817 )

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following (in thousands): Estimated Useful Life (Years) June 30, 2018 December 31, 2017 Machinery and equipment 3-10 $ 15,061 $ 12,358 Furniture and fixtures 3-5 1,083 1,083 Computer equipment and software 3-5 635 628 Buildings Up to 39 7,824 7,995 Land Indefinite 502 513 Construction in-process 1,387 1,133 26,492 23,710 Less: Accumulated depreciation (9,418 ) (8,481 ) Total $ 17,074 $ 15,229

Net (Loss) Income Per Common 30

Net (Loss) Income Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Calculation of Basic and Diluted Income (Loss) Per Common Share and Common Share Equivalents	The calculation of basic and diluted income (loss) per common share and common share equivalents is as follows (in thousands except for per share data): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Basic net (loss) income per common share Net loss $ (1,514 ) $ (376 ) $ (742 ) $ (1,817 ) Add: Excess of carrying value of Series C Preferred Stock over redemption value — 459 459 Less: Preferred stock dividends — (7 ) — (14 ) Net (loss)income applicable to common stock $ (1,514 ) $ 76 $ (742 ) $ (1,372 ) Basic weighted average number of common shares outstanding 11,103 10,803 11,023 10,803 Basic net (loss) income per common share $ (0.14 ) $ 0.01 $ (0.07 ) $ (0.13 ) Diluted income (loss) per common share Net (loss) income applicable to common stock $ (1,514 ) $ 76 $ (742 ) $ (1,372 ) Less: Excess of carrying value of Series C Preferred Stock over redemption value — (459 ) — — Add: Preferred stock dividends — 7 — — Net loss applicable to dilutive common stock $ (1,514 ) $ (376 ) $ (742 ) $ (1,372 ) Basic weighted average number of common shares outstanding 11,103 10,803 11,023 10,803 Effect of dilutive securities Dilutive stock awards — 40 — — Dilutive preferred share conversion 111 — 151 — — Diluted weighted average number of common shares outstanding 11,103 10,954 11,023 10,803 Diluted net (loss) income per common share $ (0.14 ) $ (0.03 ) $ (0.07 ) $ (0.13 )

Accumulated Other Comprehensi31

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Changes to accumulated other comprehensive loss during the six months ended June 30, 2018 were as follows (in thousands): Translation Adjustment Balance—December 31, 2017 $ (3,157 ) Current period other comprehensive income (596 ) Balance—June 30, 2018 $ (3,753 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2018
Schedule of Stock-Based Compensation Expense Allocation	Stock-based compensation expense for the three months ended June 30, 2018 and 2017 was $0.5 million and $0.5 million, respectively. Stock-based compensation expense for the six months ended June 30, 2018 and 2017 was $1.1 million and $0.8 million, respectively. Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective awards as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Cost of revenues $ 39 $ 31 $ 77 $ 59 Sales and marketing 12 12 25 23 Research and development 40 71 58 28 General and administrative 412 390 909 735 Total $ 503 $ 504 $ 1,069 $ 845
Employees [Member]
Assumptions Used to Value Options Granted	The weighted-average grant date fair values of options granted to employees during the six months ended June 30, 2018 and 2017 were $3.40 and $2.43, respectively, using the following assumptions Six Months Ended June 30, 2018 2017 Risk free interest rate 2.15% 1.45% - 1.59% Expected term 4.75 years 4.5 - 4.75 years Dividend yield — — Expected volatility 47.79% - 47.86% 53.15% - 55.20%

Restructuring Charges (Tables)

Restructuring Charges (Tables)	6 Months Ended
	Jun. 30, 2018
Restructuring And Related Activities [Abstract]
Summary of Components of Restructuring Activity	The following table summarizes the components of the Company’s restructuring activity recorded in the accompanying balance sheets (in thousands): Amounts accrued at December 31, 2017 Expense incurred Amounts paid Amounts accrued at June 30, 2018 Employee severance, benefits and related costs $ 72 $ — $ (72 ) $ — Obligations under manufacturing and development contracts 283 — (134 ) 149 $ 355 $ — $ (206 ) $ 149

Revenue from Contracts with C34

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Jun. 30, 2018
Revenue From Contract With Customer [Abstract]
Summary of Changes in Deferred Revenue Balance for Product and Service Revenue	A summary of changes in deferred revenue balances for product and service revenue is as follows: Product Revenue Service Revenue Total Opening Balance - December 31, 2017 $ 5,888 $ 253 $ 6,141 Additions 300 917 1,217 Recognized into Revenue (230 ) (538 ) (768 ) Recognized into Accumulated Deficit (5,703 ) — (5,703 ) Ending Balance - June 30, 2018 $ 255 $ 632 $ 887

Interim Condensed Consolidate35

Interim Condensed Consolidated Financial Statements - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Cash and cash equivalents	$ 20,826	$ 21,446

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory Net Items Net Of Reserve Alternative [Abstract]
Raw materials	$ 1,382	$ 1,921
Work in process	4,060	3,299
Finished goods	838	1,106
Total	$ 6,280	$ 6,326

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Inventory Net Items Net Of Reserve Alternative [Abstract]
Inventory reserve balance	$ 200,000		$ 200,000		$ 500,000
Charges for excess and obsolete inventory	$ 0	$ 0	$ 11,000	$ 200,000

Goodwill and Intangible Asset38

Goodwill and Intangible Assets - Schedule of Changes to Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning balance	$ 9,123
Effects of foreign currency translation	(195)
Ending balance	$ 8,928

Goodwill and Intangible Asset39

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Acquired Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 0.1	$ 0.1	$ 0.2	$ 0.2
Minimum [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated useful live of definite lived intangible assets			3 years
Maximum [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated useful live of definite lived intangible assets			7 years

Goodwill and Intangible Asset40

Goodwill and Intangible Assets - Changes to Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,910	$ 2,910
Foreign currency translation adjustment	(477)	(430)
Accumulated amortization	(1,846)	(1,736)
Balance	587	744
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	300	300
Foreign currency translation adjustment	(53)	(53)
Accumulated amortization	(247)	(247)
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,370	1,370
Foreign currency translation adjustment	(223)	(198)
Accumulated amortization	(888)	(839)
Balance	259	333
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,240	1,240
Foreign currency translation adjustment	(201)	(179)
Accumulated amortization	(711)	(650)
Balance	$ 328	$ 411

Goodwill and Intangible Asset41

Goodwill and Intangible Assets - Amortization Expense Remaining on Existing Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
Remainder of 2018	$ 142
2,019	256
2,020	189
Total	$ 587	$ 744

Debt and Other Contractual Ob42

Debt and Other Contractual Obligations - Additional Information (Detail)	1 Months Ended		3 Months Ended	6 Months Ended
	May 31, 2017Facility	Sep. 30, 2013USD ($)	Mar. 31, 2017USD ($)Loan	Jun. 30, 2018USD ($)Facility	Jun. 30, 2017USD ($)
Debt Instrument [Line Items]
Amount owe under loan facility				$ 2,255,000
Lease agreement term				39 months
Lease agreement, expiration year				2,019
Lease agreement rent free period				3 months
Loans entered					$ 1,501,000
Loan for Equipment [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Amount owe on equipment loans				$ 1,200,000
Loans entered			$ 1,500,000
Number of loans | Loan			2
Loans payment maturity month and year			2022-03
Capital lease term			60 months
Loan for Equipment [Member] | Loan One [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Interest rate at the end of period			2.09%
Loan for Equipment [Member] | Loan Two [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Interest rate at the end of period			2.09%
Juniper Pharma Services [Member]
Debt Instrument [Line Items]
Debt assumed		$ 3,900,000
Number of loan facilities | Facility				3
Number of loan facilities repaid | Facility	1
Gain loss on refinancing of debt				$ 0
Amount owe under loan facility				$ 2,300,000
Weighted average interest rate for the period				2.76%
Juniper Pharma Services [Member] | Minimum [Member]
Debt Instrument [Line Items]
Loan facilities repayment period				7 years
Juniper Pharma Services [Member] | Maximum [Member]
Debt Instrument [Line Items]
Loan facilities repayment period				15 years
Juniper Pharma Services [Member] | Loan Facility One [Member]
Debt Instrument [Line Items]
Loan facilities bear interest rate				1.95%
Loan facility interest rate description				base rate plus 1.95%
Weighted average interest rate at the end of period				2.45%
Juniper Pharma Services [Member] | Loan Facility Two [Member]
Debt Instrument [Line Items]
Loan facilities bear interest rate				2.55%
Loan facility interest rate description				base rate plus 2.55%
Weighted average interest rate at the end of period				3.05%
Juniper Pharma Services [Member] | Loan Facility Three [Member]
Debt Instrument [Line Items]
Loan facilities bear interest rate				2.99%

Debt and Other Contractual Ob43

Debt and Other Contractual Obligations - Summary of Future Contractual Obligations (Detail) $ in Thousands	Jun. 30, 2018USD ($)
Debt Disclosure [Abstract]
Operating lease obligations, Total	$ 296
Operating lease obligations, Remainder of 2018	222
Operating lease obligations, 2019	74
Loan principal repayments, Total	2,255
Loan principal repayments, Remainder of 2018	116
Loan principal repayments, 2019	237
Loan principal repayments, 2020	243
Loan principal repayments, 2021	250
Loan principal repayments, 2022	257
Loan principal repayments, Thereafter	1,152
Capital lease obligations, Total	1,198
Capital lease obligations, Remainder of 2018	154
Capital lease obligations, 2019	317
Capital lease obligations, 2020	331
Capital lease obligations, 2021	344
Capital lease obligations, 2022	52
Minimum purchase obligation, Total	5,375
Minimum purchase obligation, Remainder of 2018	3,401
Minimum purchase obligation, 2019	1,974
Total	9,124
Remainder of 2018	3,893
2,019	2,602
2,020	574
2,021	594
2,022	309
Thereafter	$ 1,152

Intravaginal Ring Technology 44

Intravaginal Ring Technology License - Additional Information (Detail) - USD ($)	Apr. 24, 2018	Jun. 30, 2018	May 31, 2018
License Agreements [Line Items]
License agreement notice period		90 days
License fee payment		$ 50,000
License fee payment beginning on the sixth anniversary		100,000
Milestone payment		$ 1,200,000
Daré Bioscience, Inc. [Member]
License Agreements [Line Items]
Licence agreement date	Apr. 24, 2018
License fee receivable			$ 250,000
License maintenance fee receivable for first two anniversaries	$ 50,000
License maintenance fee receivable for each anniversary, thereafter year two	100,000
Milestone payment receivable	43,800,000
Daré Bioscience, Inc. [Member] | Development Milestones [Member]
License Agreements [Line Items]
Milestone payment receivable	13,500,000
Daré Bioscience, Inc. [Member] | Sales Milestone [Member]
License Agreements [Line Items]
Milestone payment receivable	$ 30,300,000
Financial Default [Member]
License Agreements [Line Items]
Cure period		15 days
Non Financial Default [Member]
License Agreements [Line Items]
Cure period		60 days

Segments and Geographic Infor45

Segments and Geographic Information - Additional Information (Detail)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018Customer	Jun. 30, 2017Customer	Jun. 30, 2018SegmentCustomer	Jun. 30, 2017Customer	Dec. 31, 2017Customer
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments | Segment			2
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Additional customers accounted for 10% or more of total revenues	0	0	0	0
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Service [Member] | Customer One [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	41.00%	28.00%	37.00%	23.00%
Customer Concentration Risk [Member] | Merck KGaA [Member] | Sales Revenue, Net [Member] | Product Segment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
Customer Concentration Risk [Member] | Merck KGaA [Member] | Accounts Receivable [Member] | Product Segment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage			100.00%		100.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of customers			1		1
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Service [Member] | Customer One [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage			47.00%		53.00%

Segments and Geographic Infor46

Segments and Geographic Information - Selected Information by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 15,310	$ 13,956	$ 30,834	$ 25,203
Total assets	67,768		67,768		$ 61,220
Total Long-lived assets	17,734		17,734		16,124
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	3,917	2,387	7,459	4,015
Total assets	20,886		20,886		21,683
Total Long-lived assets	345		345		523
Switzerland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	9,518	9,759	19,796	17,516
Total assets	7,362		7,362		1,366
Total Long-lived assets	1,257		1,257		535
Nottingham, UK Facility [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	1,182	1,088	1,975	2,037
Total assets	39,491		39,491		38,129
Total Long-lived assets	16,129		16,129		15,064
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	693	$ 722	1,604	$ 1,635
Total assets	29		29		42
Total Long-lived assets	$ 3		$ 3		$ 2

Segments and Geographic Infor47

Segments and Geographic Information - Schedule of Other Information by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues
Product revenues	$ 9,343	$ 9,569	$ 19,417	$ 17,295
Service revenues	5,717	4,387	11,167	7,908
License revenues	250		250
Total revenues	15,310	13,956	30,834	25,203
Cost of product revenues	6,158	5,303	12,174	9,617
Cost of service revenues	2,959	2,347	5,969	4,590
Total cost of revenues	9,117	7,650	18,143	14,207
Gross profit	6,193	6,306	12,691	10,996
Total operating expenses	8,136	6,662	13,618	12,807
Total non-operating income	729	(20)	485	(6)
Loss before income taxes	(1,214)	(376)	(442)	(1,817)
Product [Member]
Revenues
Product revenues	9,343	9,569	19,417	17,295
License revenues	250		250
Total revenues	9,593	9,569	19,667	17,295
Cost of product revenues	6,158	5,303	12,174	9,617
Total cost of revenues	6,158	5,303	12,174	9,617
Gross profit	3,435	4,266	7,493	7,678
Service [Member]
Revenues
Service revenues	5,717	4,387	11,167	7,908
Total revenues	5,717	4,387	11,167	7,908
Cost of service revenues	2,959	2,347	5,969	4,590
Total cost of revenues	2,959	2,347	5,969	4,590
Gross profit	$ 2,758	$ 2,040	$ 5,198	$ 3,318

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 26,492	$ 23,710
Less: Accumulated depreciation	(9,418)	(8,481)
Total	17,074	15,229
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 15,061	12,358
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 1,083	1,083
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 635	628
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 7,824	7,995
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	39 years
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 502	513
Property, plant and equipment useful life (in years)	Indefinite
Construction in-Process [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 1,387	$ 1,133

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 0.5	$ 0.5	$ 1.1	$ 0.9
Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment purchased under equipment loans	$ 1.5		$ 1.5		$ 1.5

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) $ in Thousands	Jun. 30, 2017USD ($)shares	Jun. 30, 2017USD ($)shares	Jun. 30, 2018shares	Jun. 30, 2017USD ($)shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016shares
Class of Stock [Line Items]
Preferred stock, redemption date			Jun. 30, 2017
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares outstanding converted into common stock	130
Each share of preferred stock converted into common stock	2.78
Preferred shares converted into common stock, shares	361	361		361
Preferred stock, shares outstanding			0		0
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding			0		0	550
Payment for redemption of preferred stock | $	$ 10	$ 10		$ 10
Amount recorded in excess of carrying value over redemption value | $		$ 459		$ 459	$ 500

Net (Loss) Income Per Common 51

Net (Loss) Income Per Common Share - Calculation of Basic and Diluted Income (Loss) Per Common Share and Common Share Equivalents (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Basic net (loss) income per common share
Net loss	$ (1,514)	$ (376)	$ (742)	$ (1,817)
Less: Preferred stock dividends		(7)		(14)
Net (loss) income available to common stockholders	$ (1,514)	$ 76	$ (742)	$ (1,372)
Basic weighted average number of common shares outstanding	11,103	10,803	11,023	10,803
Basic net (loss) income per common share	$ (0.14)	$ 0.01	$ (0.07)	$ (0.13)
Diluted income (loss) per common share
Net (loss) income applicable to common stock	$ (1,514)	$ 76	$ (742)	$ (1,372)
Add: Preferred stock dividends		7		14
Net loss applicable to dilutive common stock	$ (1,514)	$ (376)	$ (742)	$ (1,372)
Basic weighted average number of common shares outstanding	11,103	10,803	11,023	10,803
Effect of dilutive securities
Dilutive stock awards		40
Dilutive preferred share conversion		111
Weighted Average Number Diluted Shares Outstanding Adjustment		151
Diluted weighted average number of common shares outstanding	11,103	10,954	11,023	10,803
Diluted net (loss) income per common share	$ (0.14)	$ (0.03)	$ (0.07)	$ (0.13)
Series C Preferred Stock [Member]
Basic net (loss) income per common share
Excess of carrying value of Series C Preferred Stock over redemption value		$ 459		$ 459	$ 500
Diluted income (loss) per common share
Excess of carrying value of Series C Preferred Stock over redemption value		$ 459		$ 459	$ 500

Net (Loss) Income Per Common 52

Net (Loss) Income Per Common Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	2	2.4	2	1.5

Accumulated Other Comprehensi53

Accumulated Other Comprehensive Loss - Schedule of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance—December 31, 2017			$ 41,512
Current period other comprehensive income	$ (1,536)	$ 823	(596)	$ 1,051
Balance—June 30, 2018	48,493		48,493
Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance—December 31, 2017			(3,157)
Current period other comprehensive income			(596)
Balance—June 30, 2018	$ (3,753)		$ (3,753)

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	Feb. 07, 2018	Jan. 08, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 503,000		$ 504,000	$ 1,069,000	$ 845,000
Stock option exercised						230,626	0
Cash received from option exercised						$ 1,400,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized			$ 3,600,000			$ 3,600,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition						2 years 6 months 29 days
Merck KGaA, Darmstandt [Member] | Germany [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of supply agreement extended		4 years 6 months
Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair values of options granted						$ 8.18	$ 5.11
Shares, vested						9,300	0
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock expired								109,550
Non-options stock outstanding			48,650			48,650		76,450
Performance-Based Restricted Stock Units [Member] | Juniper Pharma Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 36,000
Non-options stock outstanding			20,850			20,850
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted						293,500	680,400
Share-based compensation arrangement by share-based payment award, award vesting period						4 years
Weighted-average grant date fair values of options granted						$ 3.40	$ 2.43
Employees [Member] | Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock granted						122,300	52,700
Employees [Member] | Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock granted						0	186,000
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted						0	0
Stock-based compensation expense			$ 0			$ 0
Reduction of stock-based compensation expense					$ 100,000		$ 100,000
Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period						3 years
Non-Employee Directors [Member] | Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock granted						5,625	51,234
Board of Director [Member] | Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				$ 100,000
Shares, vested	27,800

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used to Value Options Granted (Detail) - Employees [Member]	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.15%
Expected term	4 years 9 months
Dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.45%
Expected term		4 years 6 months
Expected volatility	47.79%	53.15%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.59%
Expected term		4 years 9 months
Expected volatility	47.86%	55.20%

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Allocation (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 503	$ 504	$ 1,069	$ 845
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	39	31	77	59
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	12	12	25	23
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	40	71	58	28
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 412	$ 390	$ 909	$ 735

Fair Value of Financial Instr57

Fair Value of Financial Instruments - Additional Information (Detail)	Jun. 30, 2018USD ($)
Fair Value Disclosures [Abstract]
Financial assets level 1 to level 2 transfers amount	$ 0
Financial assets level 2 to level 1 transfers amount	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Taxes And Tax Related [Line Items]
Income tax expense	$ 300,000	$ 0	$ 300,000	$ 0
Global intangible low tax income included in taxable income			$ 2,400,000
Measurement period for record provisional amount			1 year
Minimum [Member]
Income Taxes And Tax Related [Line Items]
Global intangible low taxed income tax rate			10.00%

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Restructuring charges		$ 800,000
Additional restructuring charges	$ 0
Restructuring payments expected to be paid in remainder of 2018	43,000
Restructuring payments expected to be paid in 2018 or beyond	$ 100,000

Restructuring Charges - Summary

Restructuring Charges - Summary of Components of Restructuring Activity (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Restructuring Cost And Reserve [Line Items]
Amounts accrued at December 31, 2017	$ 355
Amounts paid	(206)
Amounts accrued at June 30, 2018	149
Employee Severance, Benefits and Related Costs [Member]
Restructuring Cost And Reserve [Line Items]
Amounts accrued at December 31, 2017	72
Amounts paid	(72)
Obligations under Manufacturing and Development Contracts [Member]
Restructuring Cost And Reserve [Line Items]
Amounts accrued at December 31, 2017	283
Amounts paid	(134)
Amounts accrued at June 30, 2018	$ 149

Revenue from Contracts with C61

Revenue from Contracts with Customers - Aditional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Revenue from Contracts with Customers [Line Items]
Adjustment to deferred revenue and accumulated deficit			$ 5,703,000
Deferred revenue	$ 887,000		887,000		$ 6,141,000
Sales and marketing	563,000	$ 410,000	$ 982,000	$ 788,000
Minimum [Member]
Revenue from Contracts with Customers [Line Items]
Engagement term			3 months
Maximum [Member]
Revenue from Contracts with Customers [Line Items]
Engagement term			6 months
Product [Member]
Revenue from Contracts with Customers [Line Items]
Adjustment to deferred revenue and accumulated deficit			$ 5,703,000
Deferred revenue	255,000		255,000		5,888,000
Service [Member]
Revenue from Contracts with Customers [Line Items]
Deferred revenue	632,000		632,000		$ 253,000
Topic 606 [Member]
Revenue from Contracts with Customers [Line Items]
Contract cost			200,000
Topic 606 [Member] | Prepaid Expenses and Other Current Assets [Member]
Revenue from Contracts with Customers [Line Items]
Contract cost			200,000
Topic 606 [Member] | License [Member]
Revenue from Contracts with Customers [Line Items]
Remaining performance obligation	0		0
Upfront consideration received			300,000
Accordance with Topic 605 [Member] | Topic 606 [Member] | Product [Member]
Revenue from Contracts with Customers [Line Items]
Revenue	10,300,000		19,000,000
Deferred revenue	6,400,000		6,400,000
Accordance with Topic 605 [Member] | Topic 606 [Member] | Service [Member]
Revenue from Contracts with Customers [Line Items]
Sales and marketing	$ 39,000		$ 11,000

Revenue from Contracts with C62

Revenue from Contracts with Customers - Summary of Changes in Deferred Revenue Balances for Product and Service Revenue (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Deferred Revenue Arrangement [Line Items]
Opening Balance - December 31, 2017	$ 6,141
Additions	1,217
Recognized into Revenue	(768)
Recognized into Accumulated Deficit	(5,703)
Ending Balance - June 30, 2018	887
Product [Member]
Deferred Revenue Arrangement [Line Items]
Opening Balance - December 31, 2017	5,888
Additions	300
Recognized into Revenue	(230)
Recognized into Accumulated Deficit	(5,703)
Ending Balance - June 30, 2018	255
Service [Member]
Deferred Revenue Arrangement [Line Items]
Opening Balance - December 31, 2017	253
Additions	917
Recognized into Revenue	(538)
Ending Balance - June 30, 2018	$ 632

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - Subsequent Event [Member] - $ / shares	Jul. 17, 2018	Jul. 02, 2018	Jul. 01, 2018
Subsequent Event [Line Items]
Common stock issued and outstanding canceled and converted into right to receive in cash			$ 11.50
Merger Agreement [Member]
Subsequent Event [Line Items]
Date of merger		Jul. 2, 2018
Cash tender offer commencement date	Jul. 17, 2018
Common stock price per share	$ 11.50
Number of business days that cash tender offer remain open from commencement date	20 days
Cash tender offer end date	Aug. 13, 2018
Meger agreement description		The obligation of Merger Sub to consummate the Offer is subject to customary conditions, including, among others, that a certain minimum number of shares of common stock be validly tendered and not validly withdrawn (“Minimum Condition”). Specifically, the Minimum Condition requires that there be validly tendered and not validly withdrawn shares of common stock that, when considered together with all other shares of common stock (if any) beneficially owned by Catalent and its affiliates (excluding any shares of common stock tendered pursuant to guaranteed delivery procedures that have not yet been received), represent more than 50% of the sum of (x) the total number of shares of the Company’s common stock outstanding at the time of the expiration of the Offer, plus (y) the aggregate number of shares of common stock then issuable to optionholders from which the Company has received notices of exercise prior to the expiration of the Offer (and as to which such shares have not yet been issued to such exercising optionholders) .
Minimum percentage that represents common stock outstanding at cash tender offer and common stock issuable to optionholders from expiration of Offer	50.00%